Most cancer-associated deaths occur due to metastasis, yet our understanding of metastasis
as an evolving, heterogeneous, systemic disease and of how to effectively treat it is still …

Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Tumor evolution is driven by the progressive acquisition of genetic and epigenetic
alterations that enable uncontrolled growth and expansion to neighboring and distal tissues …

Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …